KRAS and neoplasm: In 2016, a seminal study demonstrated that adoptive transfer of expanded TILs specific for Gly 12 to Asp mutation in KRAS (KRAS-G12D) lead to tumor regression in a patient with metastatic colorectal cancer (51).